Investigation of HTR3C mutations for association with 5HT3 receptor antagonist anti-emetic efficacy

Pharmacogenomics

Volumn 9, Issue 8, 2008, Pages 1027-1033

  Ward, Michael B ^a   Kotasek, Dusan ^b   McKinnon, Ross A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b Ashford Cancer Centre   (Australia)

Author keywords

5HT3 receptor antagonist; Anti emetic; Denaturing high performance liquid chromatography; Serotonin receptor

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DNA; DOLASETRON MESILATE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA SEQUENCE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ANTIEMETICS; GENE FREQUENCY; GENETIC VARIATION; HAPLOTYPES; HUMANS; MUTATION; NAUSEA; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; VOMITING;

EID: 50249175917     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.8.1027     Document Type: Article

References (16)

1. 3 antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 55(2), 173-189 (1998).
2. Sanwald P, David M, Dow J: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Drug Metab. Dispos. 24(5), 602-609 (1996).
3. Sachse C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2), 284-295 (1997).
4. Kaiser R, Sezer O, Papies A et al.: Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotype. J. Clin. Oncol. 20(12), 2805-2811 (2002).
5. Babaoglu M, Bayar B, Aynacioglu A et al.: Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin. Pharmacol. Ther. 78(6), 619-626 (2005).
6. Connolly C, Wafford K: The Cys-loop superfamily of ligand-gated ion channels: the impact of receptor structure on function. Biochem. Soc. Trans. 529-534 (2004).
7. 3 receptor: a model ligand-gated ion channel. Mol. Membr. Biol. 19(1), 11-26 (2002).
8. 3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 310, 101-111 (2003).
9. Hannon J, Hoyer D: Serotonin receptors and systems: endless diversity? Acta Biologica Szegediensis 46(1-2), 1-12 (2002).
10. 3 receptor antagonists. Pharmacogenetics 14(5), 271-278 (2004).
11. Tremblay P-B, Kaiser R, Sezer O et al.: Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J. Clin. Oncol. 21(11), 2147-2155 (2003).
12. National Cancer Institute: Common Toxicity Citeria. National Cancer Institute (1998).
13. Hesketh P: Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4, 191-196 (1999).
14. Rohde K, Fuerst R: Haplotyping and estimation of haplotype frequencies for closely linked biallelic multilocus genetic phenotypes including nuclear family information. Hum. Mutat. 17(4), 289-295 (2001).
15. Schaeffeler E, Schwab M, Eichelbaum M, Zanger U: CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum. Mutat. 22(6), 476-485 (2003).
16. 3 receptors. Nature 424(6946), 321-324 (2003).